The ANRS NAMSAL study has compared the efficacy of dolutegravir-based treatment with efavirenz 400 mg in over 600 participants living with HIV. The results show that dolutegravir-based treatment is not inferior to efavirenz, and it is considered a valid treatment option for first-line treatment in low and middle-income countries.
A mathematical model developed by Sylvie Deuffic-Burban assesses the efficacy and cost-effectiveness of different screening strategies, including universal screening. The results show that universal screening is associated with better life expectancy adjusted for quality of life than other strategies.
The ACTA trial found that a 1-week induction treatment of amphotericin B and flucytosine significantly reduced mortality in HIV-infected patients with cryptococcal meningitis. This new therapeutic regimen could save over 80,000 lives per year.
The STATIS trial found that intensive tuberculosis screening was as effective as systemic antituberculosis therapy in reducing mortality among severely immunosuppressed HIV-infected adults. The study's results suggest that both strategies can be used to improve outcomes in resource-limited settings.
Researchers discovered that a biological clock protein can alleviate symptoms and increase survival rates in fulminant hepatitis by regulating inflammation. The study found that injecting a molecule potentiating the action of this protein reduced the inflammatory response and improved outcomes.
Long-term follow-up confirms that isoniazid prophylaxis reduces both severe morbidity and mortality among HIV-infected individuals. The study provides evidence for the WHO recommendation of isoniazid preventive therapy in HIV-positive patients, even with early antiretroviral treatment.
The study found dual therapy with lamivudine and a boosted protease inhibitor to be effective as second-line treatment in patients infected by HIV with multiple mutations. The combination resulted in lower rates of treatment failure, increased CD4 cell count, and better tolerability compared to monotherapy.
The ANRS CohMSM study found an annual incidence rate of 4.8% among West African MSM, indicating they are eligible for PrEP. The study also showed a demand for access to follow-up and screening services, with 82% of participants attending their first appointment.
A randomized trial in South Africa found that screening at home and immediate antiretroviral treatment reduce HIV transmission, but only 4 out of 10 seropositive people had undetectable viral loads. The study highlights the need to improve entry into healthcare systems for those diagnosed with HIV.
The study confirms on-demand PrEP is a highly effective method of reducing the risk of HIV infection. The results show an incidence rate of 0.19 infections per 100 person-years of follow-up, with a significant drop in condom use among participants.
The ANRS 162-4D trial found that patients on a 4-day a week regimen had undetectable viral loads for most of the study period. The innovative strategy aims to improve adherence and reduce drug burden, but more research is needed to confirm its efficacy.